Evidence map›Paper›PMID 41181159›Full record

ReviewFrontiers in immunology2025

Rapidly progressive anti-GBM disease secondary to long-standing rheumatoid arthritis: a case report and literature review.

Ji Li, Jing Zhang, Sheng-Guang Li, Qian Guo, Jing Xu, Lina Zhang, Yadan Zou, Ting Long, Ruohan Yu, Yanfeng Zhang

Abstract readCase ReportsReview
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ji Li *Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Jing Zhang *Department of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Sheng-Guang LiDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Qian GuoDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Jing XuDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Lina ZhangDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Yadan ZouDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Ting LongDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Ruohan YuDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.
Yanfeng ZhangDepartment of Rheumatology and Immunology, Peking University International Hospital, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Long-standing rheumatoid arthritis (RA) complicated by anti-glomerular basement membrane (anti-GBM) disease is exceptionally rare. Case: A 71-year-old man with long-standing seropositive RA developed a rapidly progressive glomerulonephritis due to anti-GBM disease, without any known drug triggers. Despite plasmapheresis (therapeutic plasma exchange), corticosteroids, and low-dose cyclophosphamide, he remained dialysis-dependent; RA activity was subsequently controlled with tocilizumab. Complications included Conclusion: This case highlights the need for early serological testing for anti-GBM disease in RA patients with unexplained hematuria/proteinuria and for immunosuppressive therapy mindful of infection risk. Additionally, our literature review identified only ten reported cases of RA with anti-GBM disease, highlighting the rarity of this condition.

Indexed as

Anti-Glomerular Basement Membrane DiseaseArthritis, RheumatoidAgedAntibodies, Monoclonal, HumanizedCOVID-19Disease ProgressionFatal OutcomeHumansMalePlasma ExchangePlasmapheresisSARS-CoV-2Antibodies, Monoclonal, Humanizedtocilizumabanti–glomerular basement membrane diseaseautoimmune diseasecase reportrapidly progressive glomerulonephritisrheumatoid arthritis

Identifiers

PMID41181159
PMCPMC12575370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.